Fresenius stock trades close to bull-case valuation as investors digest health care outlook

Fresenius SE & Co. KGaA (ISIN DE0005785604) stock is indicated at EUR 47.08 as of August 17, 2026, in current comparative valuation data that map the share price against a range of estimated fair values.

Valuation corridor puts Fresenius price near upper scenario

A comparative valuation overview dated August 17, 2026 sets a central fair value for Fresenius shares at EUR 32.15, flanked by a bear-case scenario of EUR 27.44 and a bull-case scenario of EUR 48.50. In that framework, the present EUR 47.08 quotation places the stock well above the central fair-value line and within EUR 1.42 of the bull-case level, suggesting the market price is trading close to the top of the stated corridor.

The same valuation snapshot highlights Fresenius at EUR 47.08 on August 17, 2026 using a visual marker plotted within the bear-fair value-bull range. From the bear case at EUR 27.44 to the current price at EUR 47.08, the spread reaches EUR 19.64, underscoring how far the shares sit above the lower scenario in this specific model. Against the EUR 32.15 central estimate, the premium of EUR 14.93 is quantitatively significant and frames the present price level as demanding in valuation terms within that comparative construct.

Price context and investor takeaway

Within the health care sector, Fresenius SE & Co. KGaA is identified with ticker FRE on the Xetra exchange, giving the EUR 47.08 quote a clear home-market reference point for investors tracking European health-care names. While broader sector metrics are not detailed in the valuation piece, the explicit mapping of Fresenius shares between EUR 27.44, EUR 32.15, and EUR 48.50 provides a numeric structure within which investors can gauge upside and downside assumptions relative to the observed EUR 47.08 level.

For investors evaluating Fresenius today, the quantified differences inside this valuation corridor stand out. The EUR 1.42 gap between the current price at EUR 47.08 and the EUR 48.50 bull case shows that, within this specific scenario framework, much of the modeled upside has already been realized in the share price by August 17, 2026. Conversely, the EUR 14.64 distance between the present price and the EUR 32.44 midpoint between bear and bull cases illustrates how far the stock would have to move to re-converge on that rough central corridor reference, which can inform risk-reward assessments even in the absence of additional fresh earnings figures.

Dialysis and health care services as core business driver

Fresenius SE & Co. KGaA operates globally as a diversified health care group with a strong presence in dialysis, hospital operations, and related services, positioning the company in structural demand segments such as chronic kidney disease treatment and acute care. Dialysis treatments and associated products remain a cornerstone of its business mix, with the group historically generating a meaningful share of revenue from serving patients who require regular renal replacement therapy across Europe, North America, and other regions.

Alongside dialysis, Fresenius is active in hospital management and health-care infrastructure services, which means that its financial performance is influenced by patient volumes, reimbursement frameworks, and efficiency gains in clinical operations. These activities integrate into national health systems and insurer networks, giving the company exposure to long-term demographic trends such as aging populations and the rising prevalence of chronic conditions. For investors, the operational scale in these segments provides context for the valuation metrics reflected in the EUR 27.44 to EUR 48.50 price corridor used in the comparative analysis.

Shares priced close to upper scenario as of August 17, 2026

As of August 17, 2026, the EUR 47.08 Fresenius share price on Xetra sits only EUR 1.42 below the EUR 48.50 bull-case scenario cited in the comparative valuation framework, underscoring how tightly the stock clusters around the top end of the stated valuation range at this point in time. That relationship between the live quotation and the bull-case threshold is central to the current narrative for Fresenius stock, since it implies limited modeled upside from the present level within that specific scenario structure while leaving a wider gap on the downside to the EUR 32.15 central fair value and the EUR 27.44 bear case.

Read more

More on Fresenius stock

Investor Relations

Investor Relations information is available via the company website.

Dialysis treatments as a representative product line

Among its health-care offerings, Fresenius is closely associated with providing dialysis treatments and related equipment for patients requiring ongoing renal support, a service line that embodies the company's role in chronic-care delivery and supports recurring revenue streams.

Current market level frames investor decisions

With Fresenius shares indicated at EUR 47.08 as of August 17, 2026 on the home-market Xetra venue, investors now make allocation decisions against a backdrop in which the stock trades well above a EUR 32.15 central fair-value scenario and close to a EUR 48.50 bull-case reference within the comparative valuation corridor.

Fact box

Company: Fresenius SE & Co. KGaA
ISIN: DE0005785604
Ticker: FRE
Exchange: Xetra
Price (as of August 17, 2026): EUR 47.08
Sector / Industry: Health care
Index membership: not specified